Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: matched placebo Clear all
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Duloxetine and aeRobic Exercise to Improve Function in VEterans With Knee Osteoarthritis (DRIVE)

NCT07649291
View directory record Official record
Conditions
Knee Osteoarthritis, Pain, Depression
Interventions
Exercise, Duloxetine, Placebo, PT referral
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals

NCT01963091
View directory record Official record
Conditions
Cocaine Dependence
Interventions
oxytocin, saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

NCT01085097
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone, Placebo, Methylprednisolone
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

A Study of NE3107 in Early Parkinson's

NCT06757010
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
NE3107, Placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Farmington Hills, Michigan • Amherst, New York • Morrisville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 1, 2026, 10:25 PM EDT
Terminated Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.

NCT01972776
View directory record Official record
Conditions
COPD
Interventions
QBM076, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine in Pathologic Skin Picking

NCT01063348
View directory record Official record
Conditions
Pathologic Skin Picking, Neurotic Excoriation, Psychogenic Excoriation, Dermatillomania
Interventions
N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

NCT02932943
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Beverly Hills, California • Costa Mesa, California • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

NCT01972217
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Olaparib, Placebo, Abiraterone, Prednisone or prednisolone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

NCT05185089
View directory record Official record
Conditions
Cough, Idiopathic Pulmonary Fibrosis
Interventions
Orvepitant Maleate, Placebo
Drug
Lead sponsor
Nerre Therapeutics Ltd.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 1, 2026, 10:25 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

NCT07558668
View directory record Official record
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
SYX-5219 Oral Capsule
Drug
Lead sponsor
Sitryx Therapeutics Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Arkansas City, Arkansas • Fremont, California • Plainfield, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 1, 2026, 10:25 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

NCT06471543
View directory record Official record
Conditions
Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Interventions
RN0361
Drug
Lead sponsor
Ikaria Bioscience Pty Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Tamarac, Florida • Versailles, Kentucky • Dilworth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 1, 2026, 10:25 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study

NCT01537315
View directory record Official record
Conditions
Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
Interventions
Hydroxychloroquine, Matching Placebo
Drug · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

NCT00549770
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 1, 2026, 10:25 PM EDT
Recruiting Phase 4 Interventional

Evaluation of Pain Treatment After Total Knee Arthroplasty

NCT07538570
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Bellaire, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 1, 2026, 10:25 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Matching placebo
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
63
States / cities
Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

NCT02576639
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CNP520, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Glendale, California • Long Beach, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Inflammatory Challenge Using Endotoxin

NCT04310423
View directory record Official record
Conditions
Alcohol Use Disorder, Inflammatory Response, Craving, Depressed Mood
Interventions
Placebo, Endotoxin
Drug · Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 1, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

NCT03517722
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Placebo, Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
16 Years to 75 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Vestavia Hills, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

NCT00592839
View directory record Official record
Conditions
Nocturnal Vasomotor Symptoms
Interventions
SCE-B, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
17
States / cities
Anaheim, California • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

NCT01518946
View directory record Official record
Conditions
Orthostatic Hypotension
Interventions
Midodrine HCl, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Boca Raton, Florida • New Port Richey, Florida • Lenexa, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance, and Neuromuscular Function in Healthy Adults

NCT07706283
View directory record Official record
Conditions
Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function
Interventions
Magnesium L-threonate, Placebo
Dietary Supplement
Lead sponsor
Barry University
Other
Eligibility
18 Years to 45 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami Shores, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

NCT03976362
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Non-small-cell Lung
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Olaparib, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Burbank, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 1, 2026, 10:25 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

NCT05025956
View directory record Official record
Conditions
Femoroacetabular Impingement
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 1, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

NCT01489345
View directory record Official record
Conditions
Healthy
Interventions
ONO-2952, ONO-2952 Matching Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 1, 2026, 10:25 PM EDT